Immunovant, Inc.

NASDAQ:IMVT

Biotechnology

Healthcare
$32.52 +2.00%

+$0.69 today

Market cap
$6.73B
Beta
0.79
P/E (TTM)
-14.3
EPS (TTM)
-$2.48
52W Low $14.32High $36.29

Volume 0.73M

Average 1.84M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2026 · Annual

Operating Income

-$532.90M

FY 2026 · Annual

Net Income

-$505.61M

FY 2026 · Annual

Income Statement

USD
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development101.81M160.26M212.93M360.92M456.66M
Selling, General & Admin54.23M48.02M57.28M77.24M76.24M
Operating Expenses156.03M208.28M270.21M438.15M532.9M
Depreciation & Amortization126K193K231K377K409K
EBITDA(156.69M)(198.28M)(258.54M)(412.57M)(504.98M)
EBITDA Margin—————
Operating Income(156.03M)(208.28M)(270.21M)(438.15M)(532.9M)
Operating Margin—————
Interest Income07.58M24.95M24.73M25.33M
Interest Expense012.48M000
Other Income / Expenses(781K)(2.68M)11.44M25.2M27.51M
Income Before Tax(156.81M)(210.95M)(258.77M)(412.95M)(505.39M)
Pre-Tax Margin—————
Income Tax Expense(84K)9K567K891K215K
Net Income(156.73M)(210.96M)(259.34M)(413.84M)(505.61M)
Net Margin—————
EPS (Basic)(1.43)(1.71)(1.88)(2.73)(2.77)
EPS (Diluted)(1.43)(1.71)(1.88)(2.73)(2.77)
Weighted Avg Shares109.68M123.08M138.1M151.57M182.42M
Weighted Avg Shares (Diluted)109.68M123.08M138.1M151.57M182.42M

IMVT Earnings Waterfall · TTM

NASDAQ:IMVT · Revenue to Net Income

Key Ratios

EPS$-2.56
Gross Margin25.0%
Net Margin-539.9%
P/E Ratio-12.4
P/S Ratio279.1

Analysis

$7.1M of revenue converted into -$509.0M of net income for the selected period. Gross margin is 25.0% and net margin is -539.9%, showing how much revenue survives after costs and taxes. EPS is $-2.56, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 12, 2026
S-3ASRS-3ASR filingNov 9, 2026
10-QQuarterly reportNov 9, 2026
8-KCurrent reportNov 9, 2026
4Statement of changes in beneficial ownershipOct 30, 2026

How much revenue does IMVT generate?

Immunovant, Inc. (IMVT) reported $0.00 of revenue in fiscal 2026.

Is IMVT profitable?

Immunovant, Inc. (IMVT) reported -$505.61M of net income.